Section 4 of 6
Clinical evidence
111 evidence topics · 23 sources
Study summaries
SELVA
Objective
Objective: change in disease severity after 24 weeks
Location and study date
Registry-reported location and actual study dates
| Field | Quoted record |
|---|---|
| Country | “United States” |
| Study start | “July 31, 2024” |
| Primary completion | “January 14, 2026” |
Study design
SELVA: registry record, identifier and masking
| Information | Source quotation |
|---|---|
| Study identifier | “NCT06239480” |
| Masking | “None (Open Label)” |
Eligibility criteria
SELVA: registry record, eligibility
| Information | Source quotation |
|---|---|
| Inclusion: age | “at least 3 years of age” |
| Inclusion: diagnosis | “clinically confirmed superficial/cutaneous microcystic lymphatic malformation” |
| Exclusion: systemic disease | “severe systemic symptoms that require systemic therapy” |
Treatment
Study outcomes
Rationale for using mLM-IGA as the primary endpoint
Clinical-interview support for endpoint selection
Statistical analysis description
Number of participants (Planned and analyzed)
SELVA: registry record, enrollment
| Information | Source quotation |
|---|---|
| Enrollment, actual | “51” |
Description of analysis sets
Summary
The primary efficacy population excluded the exploratory participant aged 3 to 5 years. Primary-endpoint missing data were handled by multiple imputation. The reported confirmatory endpoints were evaluated through a prespecified testing hierarchy.
SELVA: efficacy analysis population
Missing data and multiplicity control
Results
Participant disposition
SELVA: completion of the 24-week efficacy evaluation period
Baseline characteristics
Baseline characteristics of the efficacy population
| Characteristic | Quoted value |
|---|---|
| Age in years, mean and range | “19.4 [6-57]” |
| Male-to-female count | “24:25” |
| Prior medical interventions | “34 (69%)” |
Efficacy results
SELVA: primary and key secondary efficacy endpoints
SELVA: additional clinician-assessed secondary efficacy endpoints
Health-related quality of life and patient-reported outcomes
SELVA: patient-reported secondary efficacy endpoints
Week-24 treatment satisfaction: overall satisfaction item
Safety results
SELVA: treatment-related adverse-event severity
SELVA: most common treatment-related adverse events
SELVA: possibly treatment-related discontinuation
Study limitations
Summary
SELVA lacked a concurrent placebo or active-treatment comparator. The primary assessment was performed by a clinician in an open-label study; blinded photographic assessment was a separate secondary endpoint. The 24-week efficacy population comprised 49 participants aged at least 6 years, while the exploratory younger cohort contributed only one treated participant. Six of 50 treated participants did not complete the efficacy evaluation period. Baseline-control and imputation methods do not eliminate all risks of expectation bias, confounding, or informative missingness. Treatment satisfaction among completers does not establish an effect on a generic health-utility measure.
PALV-06
Objective
Objective: safety and efficacy of topical QTORIN rapamycin
Location and study date
PALV-06: study setting
Study completion period
Study design
Eligibility criteria
PALV-06: age eligibility
Treatment
Study outcomes
Rationale for using Treatment-Emergent adverse events as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled population
| Population | Quoted number |
|---|---|
| Participants enrolled | “12” |
Description of analysis sets
Efficacy analysis: nominal significance and paired comparisons
Formal analysis-set definitions
No evidence found.
Results
Participant disposition
PALV-06: discontinuations
| Information | Source quotation |
|---|---|
| Discontinuations | “No study participants discontinued” |
Baseline characteristics
No evidence found.
Efficacy results
PALV-06: phase 2 efficacy, clinician-reported endpoint
Clinician-rated response: much improved or very much improved
Health-related quality of life and patient-reported outcomes
PALV-06: phase 2 efficacy, patient-reported endpoint
Additional quality-of-life instrument collected
Numerical dermatology life quality index results
No evidence found.
Safety results
PALV-06: phase 2 safety
| Information | Source quotation |
|---|---|
| Serious adverse events | “No serious adverse events” |
| Most common treatment-related adverse events | “application site pain (n=3, 25.0%), application site pruritus (n=3, 25.0%), and nausea (n=2, 16.7%).” |
Study limitations
Summary
PALV-06 enrolled 12 participants in an open-label, baseline-controlled study with 12 weeks of treatment. There was no concurrent comparator. Efficacy testing was exploratory, with nominal p-values and no adjustment for multiplicity. The sample size and duration limit assessment of uncommon adverse events and durability after treatment cessation. The abstract identifies a dermatology life quality index assessment but does not provide its numerical results.
WMU-NPC-1
Objective
Efficacy, safety, and concentration selection
“It aimed to evaluate the efficacy and safety of topical sirolimus gel (NPC-12G) and to estimate the optimal concentration for treatment of cutaneous lesions of VAs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The efficacy, safety, and optimal concentration of topical sirolimus gel for treatment of cutaneous lesions of vascular anomalies requires evaluation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
No evidence found.
Study design
Multicenter randomized parallel-group study
Eligibility criteria
Age and lesion requirements for entry
“Patients who are at least 1 month old” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“patients with target lesions that did not show a tendency to regress within 4 weeks based on interviews and which were visible in photographs” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Exclusions for prior mTOR inhibitor and local treatment
“Patients who had received oral treatment with mTOR inhibitors (sirolimus, everolimus, temsirolimus, etc.) within the 12 weeks prior to registration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who had received treatment for the target lesion (surgical treatment, endovascular treatment, laser therapy, phototherapy, liquid nitrogen therapy, or elastic bandage) within 3 months prior to registration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with severe erosions or ulcers on the target lesion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Alternative sirolimus gel concentrations and treatment schedule
| Field | Quoted value |
|---|---|
| Lower active concentration | “0.2%”View highlighted excerpt for this quote |
| Higher active concentration | “0.4%”View highlighted excerpt for this quote |
| Schedule | “twice per day for 12 weeks.”View highlighted excerpt for this quote |
Study outcomes
Rationale for using photographic overall improvement score as the primary endpoint
Independent photographic assessment at week 12
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled participants by diagnosis
| Diagnosis | Quoted count |
|---|---|
| Venous malformation | “27”View highlighted excerpt for this quote |
| Lymphatic malformation | “14”View highlighted excerpt for this quote |
| Tufted angioma | “8”View highlighted excerpt for this quote |
| Kaposiform hemangioendothelioma | “1”View highlighted excerpt for this quote |
Description of analysis sets
Safety, full analysis, and per protocol sets
“all 50 enrolled subjects were included in the safety analysis set” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were also no case excluded from the full analysis set as there were no violations of eligibility criteria that could have affected efficacy, making the same population as the safety analysis set.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“one case in the 0.2% group and two cases in the 0.4% group were excluded from the per protocol set due to low compliance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Baseline characteristics
No evidence found.
Efficacy results
Primary endpoint: comparisons with placebo
| Active concentration | Quoted p-value |
|---|---|
| 0.2% gel | “0.410”View highlighted excerpt for this quote |
| 0.4% gel | “0.549”View highlighted excerpt for this quote |
Primary endpoint: investigator conclusion
“There was no statistically significant difference in the mean improvement score in the 0.2% group (p = 0.410) or the 0.4% group (p = 0.549) compared with in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, we could not prove the efficacy of topical sirolimus for cutaneous vascular anomalies in this protocol.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Secondary and post hoc lesion-size findings
“the improvement in target lesion size at Week 12 assessed by the committee as one of the 16 secondary endpoints was significantly higher in the 0.4% sirolimus gel group than in the placebo group (p = 0.031).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the post-hoc analysis outside the protocol tracing the contour of the lesion, the percentages of patients with ≥20% reduction in the lesion area increased dose-dependently (0%, 37.5%, and 65.0% in the placebo, 0.2%, and 0.4% group, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Application-site adverse events in the 0.4% group
Overall safety assessment
“Regarding safety, irritation and dermatitis at the application site occurred in the 0.4% gel group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The safety data demonstrated topical sirolimus to have an acceptable safety profile.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
This randomized study evaluated 0.2% and 0.4% topical sirolimus gels, not QTORIN rapamycin 3.9% gel. The diagnostic counts total 50 participants, including 14 with lymphatic malformations. Neither active concentration differed significantly from placebo on the primary photographic improvement endpoint. A lesion-size finding was one of 16 secondary endpoints, and the lesion-area responder analysis was post hoc. The heterogeneous population and different formulations limit application of these results to QTORIN or specifically to microcystic lymphatic malformations.
Investigator-stated limitation and call for confirmatory evidence
“As a primary endpoint, this trial failed to demonstrate the efficacy of sirolimus gel for VA skin lesions. However, secondary endpoint and post-hoc analyses showed the possibility that sirolimus gel reduced the size of lesions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“To confirm these findings, a precise, long-term, randomized clinical trial with a larger patient group that focuses on lesion size as an endpoint is necessary.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
TOPICAL
Objective
Objective: comparison of topical sirolimus with vehicle
Location and study date
Protocol publication: planned recruitment start
Study design
Randomized vehicle-controlled design with matched areas within each participant
Eligibility criteria
Treatment
Topical treatment during the blinded comparison period
| Field | Quoted value |
|---|---|
| Sirolimus concentration | “0.1%” |
| Application schedule | “once daily for 12 weeks” |
Study outcomes
Rationale for using physician global assessment as the primary endpoint
Clinical relevance of change on the primary severity scale
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the published protocol
| Population | Quoted number |
|---|---|
| Planned participants | “55” |
Description of analysis sets
Summary
The protocol specifies paired Student t tests for the within-participant severity comparison and multiple imputation for missing primary outcomes.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
The retrieved publication is a protocol rather than a results report. It describes a matched-area, vehicle-controlled comparison during the first 12 weeks, followed by treatment of the whole malformation. The within-person design depends on the comparability of lesion areas and avoidance of treatment contamination between areas. The authors note that systemic absorption could reduce differences between treated and control areas. This 0.1% cream protocol does not establish the efficacy or safety of QTORIN rapamycin 3.9% gel.
TOPGUN
Objective
Location and study date
Study design
Randomized timing of treatment introduction
| Field | Quoted value |
|---|---|
| Allocation ratio across four sequences | “1:1:1:1” |
Eligibility criteria
Treatment
Study outcomes
Rationale for using physician global assessment as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Sample-size rationale in the protocol
Description of analysis sets
Summary
The planned mixed-effects linear model includes a participant-specific random intercept for repeated severity measurements. Missing observations are not imputed.
Missing-data handling
Results
Participant disposition
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
The publication reports a stepped-wedge protocol, not final efficacy or safety results. There is no placebo intervention. Participants and investigators know when treatment starts, although the photographic adjudication committee is blinded. No formal sample-size calculation was performed. The analysis plan models repeated severity measurements, but does not impute missing observations. Local application of a 1 mg/mL oral solution to lingual lesions is not equivalent to cutaneous QTORIN rapamycin 3.9% gel.
Topical sirolimus 0.2% single-center interventional study
Objective
No evidence found.
Location and study date
No evidence found.
Study design
No evidence found.
Eligibility criteria
No evidence found.
Treatment
No evidence found.
Study outcomes
Rationale for using an unreported outcome measure as the primary endpoint
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
No evidence found.
SIR-DA-0901
Objective
Location and study date
Recruitment interval
| Field | Quoted value |
|---|---|
| Recruitment began | “October 2009”View highlighted excerpt for this quote |
| Recruitment ended | “April 2013”View highlighted excerpt for this quote |
Study design
Eligibility criteria
Treatment
Oral sirolimus dosing and target exposure
| Field | Quoted value |
|---|---|
| Starting dose per administration, mg/m² | “0.8”View highlighted excerpt for this quote |
| Target trough concentration, ng/mL | “10 to 15”View highlighted excerpt for this quote |
Study outcomes
Rationale for using composite functional, quality-of-life, and radiologic response as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled and evaluable populations
| Population | Quoted number |
|---|---|
| Enrolled | “Sixty-one”View highlighted excerpt for this quote |
| Evaluable at course 6 | “57”View highlighted excerpt for this quote |
| Evaluable at course 12 | “53”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
Discontinuations for persistent adverse effects
| Outcome | Quoted count |
|---|---|
| Participants taken off study medication | “Two”View highlighted excerpt for this quote |
Baseline characteristics
Baseline age and updated diagnostic classification
| Characteristic | Quoted value |
|---|---|
| Median age in years | “8.1”View highlighted excerpt for this quote |
| Participants classified as having microcystic lymphatic malformations | “5”View highlighted excerpt for this quote |
Efficacy results
Response at the end of course 6
| Response | Quoted count |
|---|---|
| Partial response | “47”View highlighted excerpt for this quote |
| Stable disease | “3”View highlighted excerpt for this quote |
| Progressive disease | “7”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
Safety results
Sirolimus-attributable toxicities of grade 3 or higher
| Toxicity category | Quoted proportion |
|---|---|
| Blood or bone marrow | “27%”View highlighted excerpt for this quote |
| Gastrointestinal | “3%”View highlighted excerpt for this quote |
| Metabolic or laboratory | “3%”View highlighted excerpt for this quote |
Study limitations
Summary
This phase 2 trial studied systemic oral sirolimus, not a topical formulation. It enrolled a heterogeneous population of complicated vascular anomalies without a concurrent comparator. The article reclassified the original diagnostic categories, leaving five participants classified as having microcystic lymphatic malformations. Outcomes from the overall population therefore cannot be treated as a microcystic-specific response estimate. The composite response definition incorporates functional and quality-of-life changes as well as imaging, so a partial response is not equivalent to radiographic lesion resolution.
PERFORMUS
Objective
Efficacy, safety, and delineation of treatment indications
Location and study date
Recruitment interval
| Field | Quoted date |
|---|---|
| First recruitment date | “September 28, 2015”View highlighted excerpt for this quote |
| Last recruitment date | “March 22, 2018”View highlighted excerpt for this quote |
Study design
Observational-phase randomized design with randomized switch time
“This multicenter, open-label, observational-phase randomized clinical trial included 59 children aged 6 to 18 years with a slow-flow vascular malformation who were recruited between September 28, 2015, and March 22, 2018, in 11 French tertiary hospital centers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants first underwent an observational period (OP) with no treatment and then switched to an interventional period (IP) when they received sirolimus. The switch time was randomized from month 4 to month 8, and the whole study period lasted 12 months for each patient” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The trial was an open-label trial. However, the primary outcome was based on an objective outcome (ie, MRI scans interpreted by a radiologist blinded to treatment periods).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Age, malformation type, and exclusions
“Criteria for eligibility were pediatric patients, aged 6 to 18 years, with a complicated slow-flow vascular malformation (VM, LM apart from pure macrocystic LM, and combined venolymphatic malformations, including syndromic forms) extending to underlying tissues (subcutaneous tissue and muscles), confirmed by magnetic resonance imaging (MRI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We did not include children younger than 6 years of age because MRI requires sedation for children of this age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We excluded children with a vascular malformation that required immediate medical treatment or individuals who had contraindications to MRI or sirolimus (allergy, immunosuppression, chronic infectious disease or cancer, liver insufficiency, cytopenia, hypercholesterolemia, pregnancy, and women of childbearing age not using birth control).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Systemic treatment exposure target
| Field | Quoted value |
|---|---|
| Sirolimus target serum concentration, ng/mL | “4-12”View highlighted excerpt for this quote |
Study outcomes
Rationale for using change in malformation volume on magnetic resonance imaging as the primary endpoint
Centralized blinded imaging as the objective measure
“The primary outcome was change in the volume of vascular malformations detected on magnetic resonance imaging scan (with centralized interpretation) per unit of time (ie, between the interventional period and the observational period).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MRI scans were centralized and interpreted by the same radiologist (B.M.), with blinding to participants’ names and protocol sequence time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment and main analysis population
| Population | Quoted count |
|---|---|
| Enrolled | “63”View highlighted excerpt for this quote |
| Main analysis | “59”View highlighted excerpt for this quote |
Description of analysis sets
Missing-data handling for the primary analysis
Results
Participant disposition
Treatment discontinuation because of adverse events
| Outcome | Quoted count |
|---|---|
| Participants discontinuing treatment | “5”View highlighted excerpt for this quote |
Baseline characteristics
Baseline malformation categories
| Category | Quoted count |
|---|---|
| Pure venous malformations | “22”View highlighted excerpt for this quote |
| Lymphatic malformations | “18”View highlighted excerpt for this quote |
| Combined malformations | “19”View highlighted excerpt for this quote |
Efficacy results
Primary volumetric comparison: overall population
Primary volumetric comparison: by malformation subtype
“Variations in the volume of vascular malformations detected on magnetic resonance imaging scans associated with the duration period were not overall significantly different between the interventional period and the observational period (all vascular malformations: mean [SD] difference, –0.001 [0.007]; venous malformations: mean [SD] difference, 0.001 [0.004]; combined malformations: mean [SD] difference, 0.001 [0.009]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, a significant decrease in volume was observed for children with pure lymphatic malformations (mean [SD] difference, –0.005 [0.005]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Investigator conclusion on the best indication for systemic sirolimus
“Pure lymphatic malformations seem to be the best indication for sirolimus therapy because evidence of decreasing lymphatic malformation volume per unit of time, oozing, and bleeding and increasing quality of life was found.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In combined malformations, sirolimus significantly reduced pain, oozing, and bleeding. Benefits seemed lower for pure venous malformations than for the 2 other subgroups, also based on symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systemic sirolimus: absence of complete regression
Health-related quality of life and patient-reported outcomes
Children with no quality-of-life impairment on the dermatology instrument
| Assessment | Quoted proportion |
|---|---|
| Baseline | “27.1%”View highlighted excerpt for this quote |
| Month 12 | “54.2%”View highlighted excerpt for this quote |
Safety results
Safety during the sirolimus intervention period
| Outcome | Quoted value |
|---|---|
| Participants with adverse events | “56”View highlighted excerpt for this quote |
| Adverse events | “231”View highlighted excerpt for this quote |
| Serious adverse events | “5”View highlighted excerpt for this quote |
| Oral-ulcer proportion | “49.2%”View highlighted excerpt for this quote |
Study limitations
Summary
PERFORMUS included children aged 6 to 18 years and did not study QTORIN. Treatment was open label, although imaging was assessed by a blinded radiologist. The primary analysis did not show an overall effect on malformation-volume change; a reduction was reported for the lymphatic subgroup. Subgroup results should not be substituted for an overall positive primary result. The authors identify inability to control for time as a confounder in the primary analysis because imaging was available at only three time points.
VASE
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Systemic sirolimus treatment
| Field | Quoted value |
|---|---|
| Starting dose in children younger than 12 years, mg/m² twice daily | “0.8” |
| Starting dose in older participants | “2 mg/day” |
| Planned treatment duration | “2 years” |
Study outcomes
Rationale for using patient-reported symptoms and functional limitation as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Interim statistical approach
Results
Participant disposition
Completion of the planned 2-year treatment period in the interim report
| Outcome | Quoted count |
|---|---|
| Participants completing treatment | “61” |
Baseline characteristics
Efficacy results
Systemic sirolimus: clinical improvement in the interim population
Post-trial personalized-regimen cohort
Health-related quality of life and patient-reported outcomes
Safety results
Adverse-event rates after switching to personalized intermittent or on-demand regimens
Study limitations
Summary
VASE was nonrandomized and included heterogeneous slow-flow vascular malformations. Its interim symptom and safety analysis did not establish a QTORIN-specific or microcystic-specific effect. The authors identify limited pediatric enrollment, small diagnostic subgroups, and limited genetic characterization. The later personalized-regimen analysis included 30 selected adults who had previously completed two years of sirolimus and experienced recurrent symptoms. Its retrospective design and selection of prior responders limit causal comparison of dosing schedules and extrapolation to children or treatment-naive participants.